Wegovy Coupon
Introduction to Wegovy Coupon
To get a Wegovy coupon, you can visit our Disount Program link. You can apply to qualify for our Annual Comitment program or our Scae weight in Commitment to get a coupon that you can use at participating pharmacies or our clinic directly to save on your Wegovy prescription.
Alternatively, you can obtain a Wegovy Savings Card directly from the drug manufacturer Novo Nordisk. This Savings Card is for individuals with commercial insurance and a valid prescription for Wegovy. It can save you up to $225 for a 28-day supply of Wegovy. To get the Savings Card, you can visit the Novo Nordisk website and fill out a form to receive your card or download and print it directly from the website.
With either option, you can save on your Wegovy prescription and make managing your weight loss journey more affordable.
Request your Wegovy® Savings Offer
To request your Wegovy® Savings Offer, you can call 888-793-1218 or visit the program’s website. If you have private or commercial insurance, you may be eligible to pay as little as $0 for a 28-day supply of Wegovy® with a maximum savings of $225 per 28-day supply for up to 12 fills. If you pay cash or your insurance does not cover Wegovy®, you can still save with the savings offer, with potential savings of up to $500 per 28-day supply.
When calling the provided phone number, be sure to have your insurance information and prescription details ready to provide to the representative. If visiting the website, you may need to fill out a form with your insurance details and prescription information to see if you qualify for the Wegovy® Savings Offer.
These savings offers can help make Wegovy® more affordable for those with different insurance situations or for those paying cash for their prescriptions. Be sure to take advantage of this program to maximize your prescription savings.
What is Wegovy®?
Wegovy® is a prescription medication used for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol. Its active ingredient is semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that works by mimicking the effects of incretin hormones, which helps regulate blood sugar levels and appetite.
Wegovy® works by stimulating insulin production, slowing down gastric emptying, and reducing appetite. It is administered by subcutaneous injection once a week. The U.S. Food and Drug Administration (FDA) approved Wegovy® for use in June 2021, following clinical trials that demonstrated its efficacy in helping patients achieve significant weight loss.
Before starting Wegovy®, patients should be aware of potential side effects, including nausea, diarrhea, vomiting, constipation, abdominal pain, and increased heart rate. It is important for individuals to speak with their healthcare provider to determine if Wegovy® is safe and appropriate for their unique medical history and health conditions. Contraindications include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Overall, Wegovy® offers a new option for individuals struggling with obesity to achieve weight loss and improve their overall health.
What is the most important information I should know about Wegovy®?
The most important safety information for Wegovy® includes potential serious side effects and contraindications. Wegovy® has been associated with the risk of thyroid tumors, including medullary thyroid carcinoma (MTC) and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is crucial not to use Wegovy® if you or your family has a history of MTC or MEN 2.
Additionally, Wegovy® may cause nausea, vomiting, diarrhea, low blood sugar, and pancreatitis. It is important to be aware of these potential side effects and seek medical attention if they occur. Contraindications for Wegovy® include a personal or family history of MTC or MEN 2, a history of pancreatitis, and a hypersensitivity to semaglutide or any of the other ingredients in Wegovy®.
Patients should discuss their medical history and any concerns with a healthcare professional before starting Wegovy®. It is essential to carefully consider the potential risks and benefits of this medication before use.
What are the possible side effects of Wegovy®?
Possible side effects of Wegovy® include gastrointestinal symptoms such as nausea, diarrhea, vomiting, and constipation. Patients may also experience low blood sugar, kidney problems, allergic reactions, changes in vision, increased heart rate, and mental changes. Additionally, there is a black box warning for thyroid cancer, with rare but serious side effects including thyroid tumors, pancreatitis, gallbladder disease, and diabetic retinopathy complications. It is important for patients to be aware of these potential side effects and to seek medical attention if they experience any concerning symptoms while taking Wegovy®.
Important Safety Information for Wegovy® (semaglutide) injection 2.4 mg
Wegovy® (semaglutide) injection 2.4 mg is a prescription medication used for chronic weight management in adults with obesity, who have a body mass index (BMI) of 30 kg/m² or greater, or who have a BMI of 27 kg/m² or greater and also have at least one weight-related comorbidity. Before starting the treatment with Wegovy®, it is crucial to be aware of the important safety information to ensure the appropriate and safe use of the medication. Understanding the potential risks and warnings associated with Wegovy® will help patients and healthcare providers make informed decisions about its use. This safety information covers important details about adverse reactions, contraindications, warnings and precautions, and other key considerations for the use of Wegovy®. It is essential for both healthcare providers and patients to have a thorough understanding of this information to minimize potential risks and maximize the benefits of using Wegovy® for weight management.
Indications and Usage
of Wegovy® (semaglutide) injection 2.4 mg in adults and pediatric patients. Wegovy® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a body mass index (BMI) of 27 kg/m^2 or greater who have at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia), or in adults with a BMI of 30 kg/m^2 or greater. It is also indicated for chronic weight management in pediatric patients aged 12 years and older with a body weight above 60 kg and an initial BMI corresponding to 97th percentile for their age and sex. The recommended dose is to be administered once weekly at any time of day, with or without food.
The Standard Savings Offer for Wegovy® is available for eligible patients with commercial insurance, or those without coverage. Eligibility restrictions apply, including that the Savings Offer is not valid for prescriptions that are reimbursed in whole or in part by Medicaid, Medicare, or any other federal or state healthcare program. The offer has a maximum annual benefit of $1800 and a maximum savings of up to $150 per prescription for patients with commercial insurance. For patients without insurance, the maximum annual benefit is $1800, and the program offers support for obtaining medication free of charge if they meet certain eligibility requirements. Additional terms and conditions apply, and patients should consult their healthcare provider to see if they are eligible.
Limitations of Use
Wegovy® (semaglutide) is a prescription medication used for chronic weight management in adults with a body mass index (BMI) of 27 kg/m² or greater who have at least one weight-related comorbidity or in adults with a BMI of 30 kg/m² or greater. However, there are certain limitations and contraindications to its use. Wegovy® should not be used in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also not be used in patients with a history of hypersensitivity to semaglutide or any of its excipients.
Coadministration of Wegovy® with other products for weight loss has not been studied and therefore should be avoided. Additionally, the safety and efficacy of combination with other weight loss products have not been established.
Wegovy® is not recommended for use in patients with a history of pancreatitis. It should be used with caution in patients with a history of diabetic retinopathy and in patients with renal impairment.
It is important to carefully consider these limitations and safety information before prescribing Wegovy® to patients to ensure its appropriate and safe use for chronic weight management.
Drug Interactions
Wegovy, a medication used for weight management, may interact with other medications due to its impact on gastric emptying and absorption. Specifically, it may affect the absorption and efficacy of certain oral medications, including insulin and sulfonylureas. This can lead to changes in blood sugar levels and may require adjustments in the dosage of these medications. It is important to monitor the effects of concomitantly administered oral medications, and healthcare providers should consider reducing the dose of insulin secretagogues or insulin when initiating Wegovy to avoid hypoglycemia.
Additionally, Wegovy may interact with antimalarial drugs, clarithromycin, warfarin, digoxin, and phenytoin. These interactions can impact the effectiveness of these medications and may require dosage adjustments or monitoring of drug levels in the blood.
Therefore, it is essential for healthcare providers to be aware of these potential interactions and to carefully monitor patients using Wegovy in combination with other medications to ensure safety and effectiveness.
Wegovy Coupon Summary
Wegovy® is not recommended for use in pregnancy due to potential risks to the fetus, as seen in animal studies. In pediatric patients aged 12 years and older, the safety and efficacy of Wegovy® have not been established. Therefore, it is not recommended for use in this population.
Adverse reactions in these specific populations may include potential harm to the fetus in pregnant women and potential unknown effects on growth and development in pediatric patients. In cases where a woman becomes pregnant while taking Wegovy®, she should discontinue the medication and consult with her healthcare provider.
When considering the use of Wegovy® in specific populations such as pregnant women and pediatric patients aged 12 years and older, healthcare providers should carefully weigh the potential benefits versus the risks. Close monitoring and regular assessment of the risks and benefits should be conducted if the decision is made to use Wegovy® in these populations. Adults of reproductive potential should be advised to use effective contraception during treatment with Wegovy® and for at least 5 months after the last dose. Overall, caution should be exercised when considering the use of Wegovy® in these specific populations.